hepat
e
viru
common
caus
acut
hepat
contrari
hepat
b
c
hepat
e
mostli
mild
infect
although
high
mortal
pregnant
women
evolv
chronic
immunocompromis
patient
ribavirin
pegyl
interferona
avail
therapi
side
effect
accept
prophylaxi
treatment
mild
infect
addit
drug
use
patient
type
eg
case
pregnanc
specif
organ
transplant
comorbid
resourcepoor
set
henc
urgent
need
better
antivir
treatment
efficaci
safe
also
pregnanc
review
concis
introduct
viru
diseas
provid
follow
discuss
avail
assay
system
potenti
molecular
target
viral
protein
host
factor
develop
inhibitor
hev
replic
final
direct
futur
research
present
hepat
e
viru
hev
fecoor
transmit
pathogen
one
common
caus
acut
hepat
worldwid
although
viru
alreadi
identifi
balayan
et
al
mani
epidemiolog
clinic
featur
becom
clear
recent
hev
respons
acut
outbreak
develop
countri
sporad
case
worldwid
recogn
problem
transplant
set
kamar
et
al
pischk
et
al
although
infect
selfresolv
hepat
e
character
high
mortal
pregnant
women
lead
chronic
infect
immunocompromis
patient
vaccin
recent
approv
chines
market
zhu
et
al
current
therapeut
option
ie
ribavirin
interferona
sever
side
effect
treatment
failur
report
may
import
potent
safe
inhibitor
hev
replic
hand
rapidli
contain
outbreak
treat
immunodefici
patient
review
gener
introduct
hev
present
follow
overview
differ
potenti
antivir
target
current
avail
method
drug
test
direct
develop
antivir
hev
suggest
genom
structur
hev
cap
positivesens
singlestrand
rna
genom
compris
untransl
region
utr
open
read
frame
orf
utr
follow
polyatract
see
fig
encod
nonstructur
protein
contain
methyltransferas
proteas
macrodomain
helicas
rnadepend
rna
polymeras
rdrp
encod
sequenc
koonin
et
al
proteas
macrodomain
hypervari
region
contain
prolinerich
hing
found
smith
et
al
overlap
orf
translat
singl
subgenom
rna
structur
protein
graff
et
al
encod
capsid
protein
consist
shell
domain
middl
domain
also
call
protrud
domain
p
also
call
guu
et
al
yamashita
et
al
protein
translat
aa
length
phosphoryl
zafrullah
et
al
uniqu
hev
close
relat
virus
although
understudi
hev
replic
cycl
seem
typic
singlestrand
rna
viru
posit
polar
see
fig
viru
particl
first
bind
heparan
sulfat
proteoglycan
hspg
host
cell
membran
kalia
et
al
transfer
unknown
cellular
membran
receptor
result
complex
intern
clathrinmedi
endocytosi
kapur
et
al
consequ
cap
viral
genom
releas
virion
uncoat
process
directli
translat
host
cell
ribosom
machineri
nonstructur
protein
thu
gener
allow
replic
viral
genom
probabl
specif
viral
replic
complex
product
subgenom
rna
translat
structur
protein
fulllength
rna
progeni
assembl
capsid
protein
viral
particl
nm
balayan
et
al
consequ
releas
cell
nonlyt
fashion
releas
hev
particl
probabl
acquir
lipid
bilay
envelop
associ
protein
remov
later
bile
salt
enter
proteas
respect
takahashi
et
al
yamada
et
al
hev
classifi
hepeviru
genu
famili
hepevirida
ictv
least
genotyp
current
recogn
smith
et
al
genotyp
sole
infect
human
genotyp
zoonot
agent
main
reservoir
domest
pig
feagin
et
al
meng
et
al
tamada
et
al
two
addit
genotyp
propos
hev
isol
japanes
wild
boar
smith
et
al
sever
virus
less
relat
hev
isol
differ
speci
includ
chicken
avian
hev
haqshena
et
al
rabbit
zhao
et
al
rat
john
et
al
bat
drexler
et
al
ferret
raj
et
al
trout
batt
et
al
fig
exact
classif
virus
remain
determin
smith
et
al
futur
discoveri
addit
hepevirus
seem
like
waterborn
outbreak
corwin
et
al
naik
et
al
genotyp
mainli
found
asia
africa
sugitani
et
al
teshal
et
al
genotyp
isol
mexico
africa
seem
less
common
maila
et
al
et
al
see
fig
estim
infect
genotyp
result
death
annual
rein
et
al
genotyp
hand
zoonot
agent
main
reservoir
domest
pig
colson
et
al
li
et
al
takahashi
et
al
genotyp
worldwid
distribut
genotyp
mostli
found
asia
miyashita
et
al
wang
et
al
howev
genotyp
also
isol
european
pig
patient
recent
hakzevan
der
hone
et
al
jeblaoui
et
al
genotyp
infect
often
result
consumpt
undercook
pig
deer
meat
may
thu
caus
sporad
case
hepat
e
although
exact
epidemiolog
data
miss
infect
seem
lot
common
initi
thought
dalton
et
al
ijaz
et
al
verslui
et
al
acut
hepat
e
character
jaundic
fatigu
gastrointestin
discomfort
etc
clinic
indistinguish
instanc
hepat
khuroo
although
mani
infect
remain
asymptomat
case
hepat
e
resolv
spontan
patient
infect
may
progress
fulmin
hepat
overal
mortal
rate
estim
eg
khuroo
teshal
et
al
one
particularli
intrigu
characterist
hepat
e
often
lethal
pregnant
women
mortal
rate
khuroo
et
al
tsega
et
al
although
observ
genotyp
infect
increas
frequenc
obstetr
complic
stillbirth
also
report
patra
et
al
underli
mechan
phenomenon
hormon
immunolog
genet
factor
etc
unclear
date
recent
find
hev
establish
chronic
infect
immunocompromis
subject
transplant
hivinfect
patient
colson
et
al
dalton
et
al
kamar
et
al
report
genotyp
thu
far
chronic
infect
rare
symptomat
sometim
mistaken
druginduc
liver
injuri
davern
et
al
chronic
hepat
e
may
lead
cirrhosi
patient
kamar
et
al
ultim
result
death
occasion
extrahepat
manifest
also
report
mostli
neurolog
complic
syndrom
neuralg
amyotrophi
fong
illahi
kamar
et
al
sood
et
al
nefrolog
manifest
glomerulonephr
kamar
et
al
evid
discuss
hepat
e
profoundli
differ
wellknown
diseas
cours
hepat
b
c
consider
portion
patient
infect
hepat
b
viru
hbv
especi
hepat
c
viru
hcv
evolv
chronic
spontan
recoveri
rule
hepat
e
chronic
diseas
thu
far
report
immunocompromis
patient
high
rate
mortal
pregnant
women
also
uniqu
hepat
e
similar
phenomena
report
hepat
b
c
frequent
use
test
diagnos
hepat
e
detect
igm
igg
antibodi
enzymelink
immunosor
fig
hev
replic
cycl
hev
particl
first
bind
heparan
sulphat
proteoglycan
hspg
consequ
transfer
unknown
function
receptor
thu
mediat
cellular
uptak
clathrinmedi
endocytosi
follow
uncoat
viral
rna
genom
releas
cytoplasm
translat
nonstructur
protein
protein
form
replic
complex
produc
new
fulllength
subgenom
viral
rna
latter
translat
capsid
protein
membran
associ
protein
known
interfer
interferona
signal
viral
rna
packag
capsid
protein
releas
cell
help
host
factor
tumor
suscept
gene
releas
particl
associ
lipid
protein
consequ
remov
bile
acid
digest
proteas
respect
bent
assay
elisa
detect
viral
rna
quantit
revers
transcript
pcr
rtpcr
presenc
igm
antibodi
indic
recent
infect
igg
antibodi
appear
later
persist
afterward
least
time
indic
past
exposur
current
elisa
suffer
larg
variabl
assay
bendal
et
al
drobeniuc
et
al
mast
et
al
therefor
requir
urgent
optim
valid
acut
infect
usual
confirm
quantit
rtpcr
eg
jothikumar
et
al
although
assay
standard
well
increas
reliabl
sinc
incub
symptomat
period
acut
hepat
e
week
success
use
antivir
drug
acut
case
hepat
e
would
depend
avail
rapid
inexpens
diagnost
test
test
also
easi
employ
resourcepoor
set
vaccin
would
effect
strategi
prevent
hev
infect
recent
hev
vaccin
base
recombin
truncat
capsid
protein
approv
china
hecolin
zhu
et
al
remain
unclear
whether
manufactur
intend
obtain
market
approv
countri
well
anoth
recombin
vaccin
success
complet
phase
clinic
trial
nepal
shrestha
et
al
develop
halt
vaccin
may
use
prophylact
measur
highrisk
patient
immunocompromis
patient
pregnant
women
would
requir
specif
clinic
trial
demonstr
protect
efficaci
popul
best
knowledg
studi
yet
report
hecolin
howev
organ
largescal
vaccin
campaign
hev
may
particularli
costeffect
given
mostli
benign
cours
infect
develop
countri
rel
low
incid
develop
world
sinc
hev
transmit
fecoor
sanitari
measur
probabl
effect
strategi
avail
prevent
viral
spread
especi
case
genotyp
often
occur
larg
waterborn
outbreak
avail
clean
drink
water
proper
dispos
wast
water
would
effect
control
strategi
genotyp
mostli
spread
contamin
food
stuff
infam
french
figatellu
sausag
made
uncook
pig
liver
berto
et
al
colson
et
al
thorough
heat
effect
kill
viru
prevent
infect
feagin
et
al
although
ineffect
hev
also
transmit
via
blood
transfus
boxal
et
al
colson
et
al
suggest
screen
donor
blood
may
warrant
addit
vertic
transmiss
hev
report
khuroo
et
al
indic
extra
caution
requir
pregnant
women
chronic
hev
infect
transplant
patient
occasion
resolv
decreas
immunosuppress
lead
spontan
clearanc
patient
kamar
et
al
approach
unsuccess
type
patient
gener
possibl
use
pegyl
interferonalpha
pegifna
ribavirin
pegifna
use
success
liver
transplant
kidney
transplant
leukemia
patient
chronic
hepat
e
alric
et
al
haagsma
et
al
kamar
et
al
c
howev
ribavirin
seem
drug
choic
case
success
treatment
report
multipl
type
transplant
patient
kamar
et
al
mallet
et
al
pischk
et
al
pischk
et
al
also
hiv
leukemia
patient
chronic
hepat
e
giordani
et
al
neukam
et
al
acut
hepat
e
seem
respond
ribavirin
treatment
well
gerolami
et
al
pischk
et
al
addit
antihev
activ
drug
confirm
vitro
debe
et
al
nevertheless
need
administ
least
month
known
sever
advers
effect
pegifna
instanc
includ
influenzalik
symptom
neuropsychiatr
side
effect
mann
et
al
ribavirin
hand
may
induc
sever
anemia
necessit
dose
reduct
kamar
et
al
pischk
et
al
reduct
may
turn
lead
treatment
failur
pischk
et
al
one
may
deem
sever
side
effect
accept
light
sever
chronic
hepat
e
case
chronic
hepat
c
well
certainli
true
drug
would
use
prophylaxi
treat
mild
infect
addit
ribavirin
pegifna
contraind
pregnant
women
specif
patient
popul
leav
avail
treatment
option
peopl
also
consid
acut
infect
larg
outbreak
develop
countri
pegifna
option
due
fact
parenter
administr
need
requir
followup
hematolog
paramet
ribavirin
treatment
difficult
implement
set
reason
state
safe
effect
treatment
hepat
e
urgent
requir
case
acut
infect
antivir
drug
would
use
shorten
period
ill
prevent
progress
fulmin
hepat
failur
applic
would
requir
rapid
diagnosi
hepat
e
see
also
section
anoth
possibl
would
use
antivir
halt
viral
spread
epidem
outbreak
fact
outbreak
occur
rather
often
refuge
camp
eg
ahm
et
al
center
diseas
control
prevent
may
repres
opportun
clinic
trial
test
prophylact
potenti
hev
inhibitor
studi
would
appropri
ethic
pointofview
pregnant
women
drug
could
lifesav
mother
child
condit
devoid
teratogen
signific
advers
effect
ideal
women
screen
regularli
rapid
sensit
hev
test
treat
soon
possibl
may
difficult
implement
develop
countri
genotyp
endem
approv
hev
inhibitor
suffici
potent
arrest
establish
fulmin
infect
modul
hormon
system
may
anoth
interest
therapeut
option
see
suggest
section
although
develop
strategi
would
requir
detail
insight
diseas
pathogenesi
chronic
infect
patient
rapid
clearanc
hev
requir
irrevers
progress
cirrhosi
occur
ideal
drug
applic
divers
rang
immunocompromis
patient
without
overt
toxic
sinc
ribavirin
treatment
rather
good
efficaci
chronic
hevinfect
patient
combin
regimen
anoth
hevinhibitor
could
envisag
current
explor
hcv
ribavirin
directact
antivir
eg
osinusi
et
al
zeuzem
et
al
may
allow
decreas
ribavirin
dosag
thu
reduc
hope
avoid
anemia
side
effect
addit
observ
slight
synergist
effect
vitro
combin
ribavirin
interferona
debe
et
al
suggest
combin
regimen
may
worth
consid
clinic
set
success
combin
therapi
alreadi
report
chronic
hevinfect
hiv
patient
dalton
et
al
develop
antivir
drug
treatment
hev
infect
commerci
reward
instanc
develop
hcv
inhibitor
debe
et
al
therefor
appear
opportun
consid
strategi
classic
discoverydevelop
complet
new
chemic
entiti
well
instanc
offlabel
use
drug
robust
antihev
activ
regist
unrel
indic
molecul
would
identifi
current
avail
method
drug
test
vitro
test
effici
cell
cultur
system
hev
recent
becom
avail
okamoto
research
group
report
genotyp
strain
replic
hepatoma
andor
lung
adenocarcinoma
cell
line
takahashi
et
al
tanaka
et
al
tanaka
et
al
cell
also
employ
cell
cultur
system
hev
berto
et
al
hand
nih
research
group
emerson
deriv
passag
viru
strain
replic
especi
hepatoma
cell
strain
deriv
chronic
infect
patient
contain
insert
human
ribosom
rna
fragment
hypervari
region
detail
analys
indic
fragment
sever
addit
mutat
contribut
improv
vitro
replic
although
replic
capac
strain
suffici
viru
yield
assay
eg
debe
et
al
overal
growth
kinet
still
rather
slow
cytopath
effect
cpe
describ
hev
strain
preclud
use
standard
virolog
techniqu
cpe
reduct
assay
plaqu
assay
addit
genotyp
replic
poorli
cell
cultur
nguyen
et
al
probabl
account
human
infect
worldwid
sever
replicon
construct
also
establish
part
structur
protein
replac
gfp
neomycin
resist
luciferas
gene
graff
et
al
shukla
et
al
report
replicon
prove
especi
use
hand
transient
transfect
cell
allow
antivir
assay
perform
debe
et
al
largescal
cellbas
screen
replicon
select
report
replicon
would
highli
conveni
anoth
possibl
strategi
identifi
novel
inhibitor
hev
replic
use
surrog
viru
recent
report
cutthroat
trout
viru
ctv
may
serv
surrog
debe
et
al
ctv
isol
spawn
trout
western
usa
hedrick
et
al
recent
studi
reveal
viru
belong
genu
hepevirida
famili
smith
et
al
remark
similar
hev
especi
consid
helicas
polymeras
sequenc
batt
et
al
debe
et
al
ctv
replic
readili
cell
cultur
allow
rtqpcrbase
viru
yield
assay
perform
debe
et
al
addit
vitro
replic
kinet
improv
repeat
passag
unpublish
result
addit
ctv
cytopath
viru
cpe
induc
cell
rather
limit
observ
nearli
complet
cpe
attain
piscin
cell
line
unpublish
result
avian
hev
also
success
employ
surrog
model
eg
kenney
et
al
pudupakam
et
al
conclus
recent
develop
consider
expand
number
assay
tool
avail
hev
antivir
studi
howev
possibl
still
rather
limit
field
would
benefit
instanc
hev
strain
improv
replic
kinet
enzymat
assay
differ
nonstructur
protein
select
report
replicon
ideal
anim
model
hev
would
small
inexpens
anim
prefer
rodent
infect
human
hev
least
close
relat
viru
develop
acut
hepat
clear
increas
liver
marker
high
viral
titer
mortal
requir
although
lethal
phenotyp
highli
use
antivir
drug
test
anim
model
mimic
hormonedepend
effect
observ
pregnant
women
would
plu
sever
anim
model
avail
vivo
hev
studi
see
tabl
overview
certain
limit
instanc
chicken
trout
use
experiment
anim
model
infect
avian
hev
ctv
respect
billam
et
al
hedrick
et
al
sinc
virus
surrog
human
hev
valid
experiment
result
would
requir
anoth
model
genuin
hev
infect
perform
pig
feagin
et
al
halbur
et
al
sanford
et
al
nonhuman
primat
macaqu
chimpanze
meng
et
al
purcel
et
al
yu
et
al
howev
ethic
concern
well
practic
issu
may
make
studi
complic
rodent
may
present
access
model
organ
instanc
laboratori
rat
experiment
infect
rat
hev
contradict
report
publish
human
hev
genotyp
li
et
al
b
purcel
et
al
zhu
et
al
success
infect
balbc
nude
mice
hev
report
huang
et
al
li
et
al
rabbit
infect
rabbit
hev
certain
genotyp
strain
cheng
et
al
final
infect
mongolian
gerbil
genotyp
also
report
due
larg
variabl
publish
result
robust
model
evalu
multipl
laboratori
yet
report
addit
none
model
result
lethal
phenotyp
predomin
genotyp
hev
primat
even
avail
model
time
promis
strategi
toward
robust
anim
model
may
infect
immunedefici
rat
mice
rat
hev
discoveri
studi
murin
hev
speci
hev
infect
mice
chimer
human
porcin
liver
meuleman
et
al
establish
transgen
mice
human
hev
receptor
identifi
done
success
polioviru
ren
et
al
hcv
dorner
et
al
hev
inhibitor
would
shown
success
surrog
anim
model
would
excel
safeti
pharmacokinet
profil
clinic
studi
would
next
stage
develop
studi
one
could
consid
treat
chronic
infect
patient
possibl
combin
regimen
ribavirin
howev
patient
may
multipl
comorbid
could
confound
factor
concomit
drug
use
lead
drugdrug
interact
sinc
hepat
e
rather
long
incub
period
clinic
symptom
often
appar
sever
week
clinic
studi
could
possibl
perform
outbreak
set
well
way
prophylact
therapeut
efficaci
may
assess
present
select
viral
host
protein
may
attract
target
antivir
therapi
see
also
tabl
entri
viru
particl
host
cell
multistep
process
involv
attach
viru
receptor
cellular
membran
intern
virionreceptor
complex
subsequ
uncoat
viral
capsid
releas
rna
genom
cytoplasm
function
hev
receptor
still
unknown
date
although
indic
genotyp
may
use
differ
receptor
genotyp
nguyen
et
al
also
found
hev
attach
hspg
specif
may
account
liver
tropism
kalia
et
al
hypothes
hspg
act
highli
abund
initi
attach
receptor
bind
hev
rel
low
affin
second
step
virion
probabl
transfer
highaffin
function
receptor
result
complex
intern
structur
determin
hevlik
particl
combin
mutat
cell
bind
studi
identifi
receptor
bind
site
top
dimer
protrud
axi
symmetri
yamashita
et
al
interestingli
site
homolog
noroviru
receptorbind
site
attach
histoblood
group
trisaccharid
guu
et
al
addit
anoth
sialic
acidbind
site
found
region
capsid
protein
guu
et
al
despit
limit
inform
avail
hev
attach
entri
sever
potenti
interest
antivir
strategi
deriv
data
first
homolog
put
hev
noroviru
receptorbind
site
suggest
noroviru
attach
inhibitor
could
possibl
interest
lead
develop
antihev
drug
confirm
noroviru
entri
inhibitor
describ
date
two
potenti
interest
prototyp
molecul
design
nmr
bind
studi
rademach
et
al
similar
way
citrat
found
compet
histoblood
group
saccharid
noroviru
bind
hansman
et
al
suggest
promis
role
glycomimet
second
possibl
overlap
approach
search
inhibitor
hev
attach
hspg
heparan
sulfat
relat
molecul
inhibit
attach
multipl
virus
vitro
vivo
eg
ali
et
al
bugatti
et
al
lee
et
al
howev
clinic
applic
molecul
remain
question
would
requir
complet
abolish
anticoagul
properti
pentosan
polysulf
oligosaccharid
deriv
approv
market
pain
relief
interstiti
cystiti
davi
et
al
given
drug
inhibit
entri
multipl
virus
baba
et
al
may
worthwhil
test
therapeut
option
hepat
e
although
still
anticoagul
properti
sculli
et
al
thirdli
shown
truncat
protein
capabl
prevent
hev
infect
vitro
et
al
truncat
protein
otherwis
mimick
receptorbind
region
hev
would
theoret
possibl
prevent
virion
bind
cellular
receptor
illustr
feasibl
approach
refer
myrcludexb
lipopeptid
deriv
hbv
envelop
protein
effici
inhibit
hbv
entri
vitro
vivo
volz
et
al
strategi
outlin
illustr
lack
identifi
receptor
import
hurdl
identif
studi
attach
entri
uncoat
inhibitor
hev
effici
cell
cultur
system
avail
eg
shukla
et
al
hiatu
address
follow
releas
viral
rna
cytoplasm
initi
translat
rna
genom
replic
rnadepend
rna
polymeras
sequenc
align
predict
rdrpencod
sequenc
end
see
fig
koonin
et
al
belong
alphavirussupergroup
rdrp
koonin
polymeras
activ
later
confirm
detect
newli
synthes
negativesens
viral
rna
vitro
agraw
et
al
rehman
et
al
rdrp
interact
stem
loop
end
viral
genom
polyatail
agraw
et
al
coloc
endoplasmat
reticulum
rehman
et
al
howev
detail
hev
rdrp
structur
function
miss
evidenc
success
nucleosid
nucleotid
inhibitor
hiv
herpesvirus
viral
polymeras
attract
target
antivir
therapi
also
rdrp
rna
virus
target
success
molecul
consid
instanc
nucleosid
analog
develop
hcv
eg
sofosbuvir
highli
activ
safe
high
barrier
resist
sofosbuvir
success
complet
phase
clinic
trial
lawitz
et
al
may
receiv
market
approv
near
futur
cmethylcytidin
cmc
relat
molecul
first
nucleosid
analog
enter
clinic
studi
treatment
hcv
infect
shown
vitro
inhibit
replic
number
positivesens
singlestrand
rna
virus
juland
et
al
rochapereira
et
al
howev
neither
cmc
number
analog
exhibit
signific
activ
transient
hev
replicon
assay
describ
debe
et
al
unpublish
result
also
moder
antivir
activ
cmc
observ
ctv
debe
et
al
despit
neg
result
nucleo
ide
analog
may
possibl
interest
inhibitor
hev
replic
moreov
research
effort
could
direct
toward
develop
rdrp
inhibitor
target
hev
distantli
relat
alphaviru
famili
broadspectrum
inhibitor
would
provid
muchneed
treatment
option
multipl
infect
neglect
virus
chikungunya
viru
sindbi
viru
equin
enceph
virus
elucid
hev
rdrp
crystal
structur
develop
conveni
enzymat
assay
would
allow
jumpstart
specif
domain
hev
antivir
research
hev
genom
cap
structur
crucial
requir
infect
cap
multistep
process
involv
hydrolysi
cphosphat
termin
nucleotid
subsequ
conjug
gmp
result
triphosph
bond
final
methyl
newli
ad
guanosin
proport
sequenc
predict
encod
viral
methyltransferas
koonin
et
al
inde
express
protein
display
guanyltransferas
activ
magden
et
al
miss
rna
triphosphatas
function
may
fulfil
hev
helicas
karp
lole
sinc
hev
heavili
depend
cap
rna
genom
infect
viral
methyltransferas
seem
ideal
target
antivir
therapi
sinc
enzymat
activ
virusspecif
magden
et
al
thu
may
allow
develop
select
inhibitor
success
target
viral
methyltransferas
describ
instanc
dengu
viru
barral
et
al
west
nile
viru
chen
et
al
moreov
highli
effici
inhibitor
chikungunya
viru
replic
select
resist
mutat
viral
methyltransferas
recent
identifi
laboratori
unpublish
result
delang
l
leyssen
p
neyt
j
indic
inhibit
transferas
may
valuabl
strategi
inhibit
replic
rna
virus
includ
hev
solv
crystal
structur
develop
robust
enzymat
assay
would
signific
advanc
rna
virus
requir
rnaunwind
activ
viral
encod
helicas
enzym
replic
energi
need
process
provid
hydrolysi
ntp
kwong
et
al
rdrp
methyltransferas
ntpase
rna
unwind
activ
predict
hev
helicas
domain
confirm
vitro
karp
lole
helicas
belong
unwind
helicas
superfamili
also
compris
alphaviru
coronaviru
cov
helicas
potent
inhibitor
identifi
sarscov
helicas
adedeji
et
al
tanner
et
al
suggest
may
also
possibl
develop
inhibitor
hev
helicas
import
caveat
inhibitor
need
highli
specif
viral
helicas
without
affect
host
helicas
activ
avoid
toxic
exampl
herpesviru
field
helicaseprimas
inhibitor
letermovir
success
finish
phase
clinic
studi
marschal
et
al
show
select
attain
besid
mention
enzym
hev
genom
encod
sever
protein
function
signific
elucid
complet
like
macro
domain
viral
proteas
protein
given
inform
would
becom
avail
may
constitut
suitabl
target
antivir
therapi
macrodomain
formerli
known
xdomain
locat
upstream
helicas
gene
fig
koonin
et
al
name
deriv
homolog
nonhiston
domain
histon
egloff
et
al
exact
function
hev
macrodomain
unclear
although
strongli
bind
poli
adpribos
egloff
et
al
import
posttransl
protein
modif
involv
cell
surviv
apoptosi
among
function
schreiber
et
al
sinc
suggest
biolog
function
viral
macrodomain
may
unrel
human
homolog
neuvonen
ahola
could
repres
attract
target
inhibit
howev
would
requir
profound
understand
function
activ
domain
secondli
papainlik
cystein
proteas
domain
predict
hev
genom
sequenc
koonin
et
al
remain
unclear
whether
proteas
fulli
function
consequ
one
enigma
hev
molecular
biolog
whether
process
discret
function
unit
sever
public
report
process
extent
parvez
ropp
et
al
sehgal
et
al
other
found
process
whatsoev
et
al
suppiah
et
al
hand
deubiquitin
activ
report
methyltransferaseproteas
fusion
domain
may
involv
combat
cellular
antivir
respons
karp
lole
recent
mutat
studi
suggest
glycinetriad
proteas
substrat
sequenc
parvez
although
viral
proteas
gener
interest
target
antivir
therapi
exemplifi
field
hiv
hcv
insight
activ
function
structur
hev
proteas
would
essenti
focus
proteas
inhibitor
encod
aa
phosphoprotein
graff
et
al
exclus
found
hepevirus
protein
dispens
vitro
infect
cultur
cell
requir
infect
seroconvers
rhesu
macaqu
graff
et
al
number
function
propos
sever
bind
partner
identifi
holla
et
al
ratra
et
al
gener
protein
seem
optim
host
cell
hev
replic
increas
cell
surviv
chandra
et
al
chandra
et
al
moin
et
al
suppress
interferona
signal
dong
et
al
addit
protein
implic
virion
egress
yamada
et
al
disrupt
blood
coagul
geng
et
al
note
result
obtain
artifici
system
ie
overexpress
protein
cultur
cell
instead
genuin
infect
hev
order
target
antivir
develop
insight
structur
function
requir
sinc
protein
multipl
cellular
bind
partner
may
interest
look
inhibitor
proteinprotein
interact
see
also
section
approach
may
yield
specif
inhibitor
hev
replic
low
toxic
high
barrier
resist
especi
given
overlap
expect
substanti
limit
number
viabl
mutat
feasibl
identifi
proteinprotein
interact
inhibitor
antivir
molecul
proven
interact
hiv
integras
instanc
christ
et
al
sinc
mani
directact
antivir
agent
prone
emerg
select
resist
virus
increas
interest
target
host
factor
coopt
virus
replic
host
factortarget
antivir
increas
barrier
resist
may
potenti
broadspectrum
activ
multipl
bind
partner
identifi
hev
structur
nonstructur
protein
function
signific
mani
interact
remain
unclear
date
host
factor
may
wellsuit
antivir
target
discuss
host
factor
believ
potenti
drugabl
first
tumor
suscept
gene
central
mediat
endosom
protein
sort
pathway
surjit
et
al
hev
protein
psapmotif
associ
thu
increas
secret
immunosuppress
local
suppress
host
immun
respons
surjit
et
al
addit
requir
virion
releas
interact
protein
psapmotif
kenney
et
al
nagashima
et
al
b
involv
virion
releas
limit
hev
also
found
essenti
hiv
ebola
viru
bud
garru
et
al
martinserrano
et
al
explor
target
antivir
therapi
instanc
cyclic
peptid
block
interact
ptap
motif
hiv
gagprotein
found
block
hiv
bud
tavassoli
et
al
moreov
express
cell
membran
hiv
influenza
viru
infect
target
antibodi
block
viru
product
bonavia
et
al
diaz
et
al
similar
question
pose
hev
hev
induc
express
cell
membran
interact
block
small
molecul
cyclic
peptid
potenti
antivir
research
hev
could
piggyback
ongo
effort
hiv
influenza
viru
thu
advanc
rapidli
anoth
interest
find
proteasom
inhibitor
inhibit
hev
replic
indic
hev
like
requir
activ
ubiquitinproteasom
system
infect
karp
meng
similar
find
report
influenza
viru
haasbach
et
al
hiv
schubert
et
al
vaccinia
viru
satheshkumar
et
al
suggest
target
proteasom
system
may
interest
strategi
identifi
broadspectrum
antivir
drug
proteasom
inhibitor
bortezomib
carfilzomib
current
use
treatment
multipl
myeloma
base
increas
suscept
cancer
cell
compar
nonmalign
cell
hideshima
et
al
howev
unknown
whether
select
also
attain
virusinfect
cell
versu
healthi
cell
avoid
sever
side
effect
similar
analysi
may
appli
heat
shock
protein
cellular
target
antihev
drug
antivir
therapi
gener
requir
intracellular
traffick
hev
particl
inhibit
geldanamycin
block
hev
infect
zheng
et
al
mani
virus
depend
replic
block
inhibitor
basha
et
al
geller
et
al
sun
et
al
inhibitor
current
develop
anticanc
therapi
jhaveri
modi
overview
question
remain
suffici
select
attain
safe
antivir
therapi
altern
strategi
may
specif
inhibit
proteinprotein
interact
hev
capsid
thu
leav
enzymat
activ
undisturb
final
multipl
indic
hev
replic
may
influenc
sex
hormon
first
mortal
increas
dramat
pregnant
women
infect
genotyp
khuroo
et
al
tsega
et
al
underli
mechan
still
unclear
known
low
progesteron
receptor
mrna
level
mutat
progesteron
receptor
gene
progin
associ
poor
pregnanc
outcom
fulmin
hepat
failur
fetal
matern
death
hev
infect
bose
et
al
hand
autochthon
hev
infect
develop
countri
seem
primarili
affect
male
dalton
et
al
davern
et
al
mansuy
et
al
report
replic
ctv
hev
surrog
viru
directli
influenc
differ
concentr
progesteron
testosteron
debe
et
al
suggest
possibl
similar
phenomenon
hev
infect
sever
potenti
strategi
deriv
limit
inform
avail
sinc
decreas
progesteron
receptor
activ
associ
poor
pregnanc
outcom
hepat
e
bose
et
al
high
concentr
progesteron
inhibit
ctv
replic
debe
et
al
one
may
consid
progesteron
supplement
pregnant
women
hepat
e
supplement
approv
fda
prevent
preterm
birth
norwitz
caughey
similarli
testosteron
level
decreas
age
low
testosteron
concentr
facilit
ctv
replic
debe
et
al
suggest
testosteron
supplement
may
benefici
elderli
man
chronic
infect
hev
third
possibl
may
use
select
estrogen
receptor
modul
serm
tamoxifen
raloxifen
serm
found
inhibit
hcv
replic
vitro
murakami
et
al
watashi
et
al
raloxifen
improv
efficaci
pegyl
interferon
ribavirin
menopaus
women
chronic
infect
hcv
furusyo
et
al
would
interest
look
effect
serm
hev
ctv
replic
may
repres
anoth
possibl
treatment
option
hepat
e
pregnanc
fulli
explor
potenti
treatment
hepat
e
modul
hormon
system
robust
anim
model
display
hormonedepend
viru
replic
would
much
appreci
antivir
drug
treatment
hepat
e
requir
acut
chronic
infect
drug
increas
potenc
efficaci
safeti
compar
current
use
ribavirin
pegifna
thu
allow
prophylact
use
contain
outbreak
prefer
treatment
pregnant
women
highrisk
patient
well
would
also
interest
character
mechan
action
ribavirin
pegifna
hepat
e
evid
discuss
hev
understudi
pathogen
suggest
antivir
strategi
requir
elabor
fundament
knowledg
molecular
virolog
addit
better
model
system
develop
vitro
vivo
proper
antivir
research
conduct
hev
extrem
interest
pathogen
deserv
profound
studi
last
decad
much
effort
gone
hcv
antivir
field
mani
candid
drug
current
advanc
clinic
develop
await
market
approv
even
market
hev
research
could
potenti
benefit
research
group
switch
main
focu
hcv
hev
